Word Recognition Performance: Using standard 35-word lists in background noise, 40.2% of the active treatment cohort achieved a meaningful gain of 4 or more correctly recognized words, compared to 27.8% of the placebo cohort, representing a 12.4% net response rate
21 (UPI) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea
Bridge, The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25
Minor water retention or numbness in extremities at higher doses
BRAND: LivOn Laboratories DIRECTIONS: As a dietary supplement, take one packet 1 to 2 times per day or as directed by a healthcare practitioner
If cleared, CagriSema would become the first injectable to combine a GLP-1 receptor agonist with an amylin analogue, a genuine mechanistic milestone regardless of the comparison with tirzepatide